Kevin Patrick Moran - 04 Mar 2024 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Signature
/s/ Kevin Patrick Moran
Issuer symbol
VNDA
Transactions as of
04 Mar 2024
Net transactions value
-$63,393
Form type
4
Filing time
06 Mar 2024, 16:46:58 UTC
Previous filing
21 Feb 2024
Next filing
29 Jul 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNDA Common Stock Sale $25,982 -5,798 -2.4% $4.48 239,916 04 Mar 2024 Direct F1, F2
transaction VNDA Common Stock Sale $37,411 -8,902 -3.7% $4.20 231,014 05 Mar 2024 Direct F1, F3
holding VNDA Common Stock 635 04 Mar 2024 By Wife
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.435 to $4.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.195 to $4.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.